Lateral flow assays sales will rise through 2036, driven by kits and reagents at a 72.0% share of the leading product segment in 2026. The market is valued at USD 4.9 billion in 2026 and is forecast to reach USD 7.7 billion by 2036 as rapid point-of-care testing spreads.